Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

被引：1
|
作者：
Morschhauser, Franck [1 ]
Flinn, Ian [2 ]
Advani, Ranjana H. [3 ]
Diefenbach, Catherine S. [4 ]
Kolibaba, Kathryn [5 ]
Press, Oliver W. [6 ]
Sehn, Laurie H. [7 ]
Chen, Andy I. [8 ]
Salles, Gilles [9 ]
Tilly, Herve [10 ]
Cheson, Bruce D. [11 ]
Assouline, Sarit [12 ]
Dreyling, Martin [13 ]
Hagenbeek, Anton [14 ]
Zinzani, Pier Luigi [15 ]
Yalamanchili, Sreeni [16 ]
Lu, Dan [16 ]
Jones, Cheryl [16 ]
Jones, Surai [16 ]
Chu, Yu-Waye [16 ]
Sharman, Jeff P. [17 ]
机构：
[1] Ctr Hosp Reg Univ Lille, Lille, France
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[4] NYU, Sch Med, New York, NY USA
[5] Northwest Canc Specialists, Vancouver, WA USA
[6] Univ Washington, Seattle, WA 98195 USA
[7] Ctr Lymphoid Canc, Vancouver, BC, Canada
[8] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[9] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France
[10] Ctr Henri Becquerel, F-76038 Rouen, France
[11] Georgetown Univ Hosp, Washington, DC 20007 USA
[12] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada
[13] Klinikum Univ Munchen Campus Grosshadern, Munich, Germany
[14] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[15] Univ Bologna, Bologna, Italy
[16] Genentech Inc, San Francisco, CA USA
[17] Willamette Valley Canc Inst US Oncol Res, Springfield, OR USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Updated results of a phase Ib/II randomised study: polatuzumab vedotin (Pola) plus bendamustine (B) and rituximab (R) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Sehn, L. H.
    McMillan, A.
    Matasar, M. J.
    Flowers, C. R.
    Kamdar, M.
    Hertzberg, M.
    Assouline, S.
    Kim, T. M.
    Kim, W. S.
    Ozcan, M.
    Croft, B.
    Herrera, A. F.
    Hirata, J.
    Cheng, J.
    Ku, G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 93 - 94
  • [32] Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
    Thiruvengadam, Swetha Kambhampati
    Mei, Matthew G.
    Chen, Lu
    Puverel, Sandrine
    Chen, Robert
    Popplewell, Leslie L.
    Nikolaenko, Liana
    Peters, Lacolle
    Armenian, Saro
    Kwak, Larry W.
    Rosen, Steven T.
    Forman, Stephen J.
    Herrera, Alex F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (10):
  • [33] A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non-Hodgkin lymphoma
    Ikoma, Yoshikazu
    Nakamura, Nobuhiko
    Kitagawa, Junichi
    Miwa, Takao
    Takada, Eri
    Matsumoto, Takuro
    Shibata, Yuhei
    Nakamura, Hiroshi
    Kanemura, Nobuhiro
    Kasahara, Senji
    Hara, Takeshi
    Sawada, Michio
    Tsurumi, Hisashi
    Shimizu, Masahito
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (01)
  • [34] SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
    Westin, Jason
    Olszewski, Adam J.
    Fogliatto, Laura
    Kim, Won Seog
    Shin, Ho-Jin
    Jeon, Young-Woo
    Norasetthada, Lalita
    Pavlovsky, Astrid
    Rego, Eduardo
    Wu, Hao
    Yin, Shen
    Batlevi, Connie Lee
    Pham, Song
    Penuel, Elicia M.
    Jing, Jing
    Wei, Michael C.
    Budde, Lihua Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
    Westin, Jason
    Olszewski, Adam J.
    Fogliatto, Laura Maria
    Kim, Won-Seog
    Shin, Ho-Jin
    Wu, Hao
    Yin, Shen
    Pham, Song
    Penuel, Elicia
    Jing, Jing
    Wei, Michael C.
    Budde, Elizabeth L.
    BLOOD, 2022, 140 : 3771 - 3772
  • [36] Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab
    Amaya, M. L.
    Jimeno, A.
    Kamdar, M.
    DRUGS OF TODAY, 2020, 56 (04) : 287 - 294
  • [37] Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma
    Yuen, Sam
    Phillips, Tycel J.
    Bannerji, Rajat
    Marlton, Paula
    Gritti, Giuseppe
    Seymour, John F.
    Johnston, Anna
    Arthur, Christopher
    Dodero, Anna
    Sharma, Sunil
    Hirata, Jamie
    Musick, Lisa
    Flowers, Christopher R.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (07) : 1281 - 1289
  • [38] Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
    Rong Shi
    Tong Lu
    Grace Ku
    Hao Ding
    Tomohisa Saito
    Leonid Gibiansky
    Priya Agarwal
    Xiaobin Li
    Jin Yan Jin
    Sandhya Girish
    Dale Miles
    Chunze Li
    Dan Lu
    Cancer Chemotherapy and Pharmacology, 2020, 86 : 347 - 359
  • [39] Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
    Herrera, Alex F.
    Moskowitz, Alison J.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Ogden, Carol Anne
    Taft, David
    Zhang, Qu
    Kato, Kazunobu
    Campbell, Mary
    Advani, Ranjana H.
    BLOOD, 2018, 131 (11) : 1183 - 1194
  • [40] Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
    Shi, Rong
    Lu, Tong
    Ku, Grace
    Ding, Hao
    Saito, Tomohisa
    Gibiansky, Leonid
    Agarwal, Priya
    Li, Xiaobin
    Jin, Jin Yan
    Girish, Sandhya
    Miles, Dale
    Li, Chunze
    Lu, Dan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (03) : 347 - 359
12345